Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 12/20 | 0.45 |
| ▸ | CYP26B1 | Q9NR63 | 10/20 | 0.45 |
| ▸ | RXRA | P19793 | 4/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HNF4A | P41235 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6146899 | 0.68 | CYP26A1 (0.69) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL18211734 | 0.66 | PTGS1 (0.41) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL7548008 | 0.64 | CYP26A1 (0.59) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL5737183 | 0.62 | CYP26A1 (0.56) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL22838106 | 0.62 | CYP26A1 (1.00) | CYP26A1CYP26B1CYP3A4RARARARB | |
| SCHEMBL6148042 | 0.62 | CYP26A1 (0.71) | CYP26A1CYP26B1RXRARXRBRXRG | |
| SCHEMBL503594 | 0.61 | CA2 (0.52) | RXRARXRBRXRGRARB | |
| SCHEMBL10137814 | 0.60 | CA2 (0.56) | RXRARXRBRXRG | |
| SCHEMBL909093 | 0.60 | CA2 (0.56) | RXRARXRB | |
| SCHEMBL10174246 | 0.59 | ALDH1A1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193578-A1 | Compounds having activity as inhibitors of cytochrome P450RAI | RARA, RARB, RARG | CYP26A1 4/4885CYP26B1 5/4885RXRA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.